Dr. Elizabeth Verna, MD
Claim this profileColumbia University Medical Center
Studies Hepatitis
Studies Diabetic Liver Disease
5 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Elizabeth Verna, MD is currently running
Hepatitis C Kidneys Transplantation
for Kidney Failure
The Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients \[THINKER-NEXT\] study will include adult kidney transplant candidates without hepatitis C virus (HCV) infection on the transplant waiting list who will consent to kidney transplantation from a deceased donor infected with HCV, followed by treatment with a direct acting antiviral. The one-year allograft function and one-year risk of CMV infection will be compared between THINKER-NEXT kidney transplant recipients and matched recipients who received hepatitis C uninfected kidney transplants (these patients are called Transplant Cohort). The survival rate of patients opting-in for offers of kidneys from HCV-viremic donors will be compared to the survival rate of matched comparators from the kidney transplant waitlist who did not consent to receive offers of a HCV-viremic kidney. Lastly, renal pathologic findings will be compared among HCV-viremic donors and HCV-negative comparator donors.
Recruiting1 award Phase 25 criteria
Siplizumab
for Autoimmune Liver Disease
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT. Up to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses. All subjects will be followed in the study for 12 months post-LT.
Recruiting1 award Phase 13 criteria
More about Elizabeth Verna, MD
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Elizabeth Verna, MD has experience with
- Siplizumab
- Epclusa
- Tenofovir Alafenamide (TAF)
Breakdown of trials Elizabeth Verna, MD has run
Hepatitis
Diabetic Liver Disease
Liver Cirrhosis
Liver Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Elizabeth Verna, MD specialize in?
Elizabeth Verna, MD focuses on Hepatitis and Diabetic Liver Disease. In particular, much of their work with Hepatitis has involved treating patients, or patients who are undergoing treatment.
Is Elizabeth Verna, MD currently recruiting for clinical trials?
Yes, Elizabeth Verna, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Elizabeth Verna, MD has studied deeply?
Yes, Elizabeth Verna, MD has studied treatments such as Siplizumab, Epclusa, Tenofovir Alafenamide (TAF).
What is the best way to schedule an appointment with Elizabeth Verna, MD?
Apply for one of the trials that Elizabeth Verna, MD is conducting.
What is the office address of Elizabeth Verna, MD?
The office of Elizabeth Verna, MD is located at: Columbia University Medical Center, New York, New York 10032 United States. This is the address for their practice at the Columbia University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.